Pharsight� Online Events Archive

Pharsight® Events

Calendar of Events

Upcoming Events

Conference Presentations, Posters & Abstracts

Recent Contributions

Events Center

Online Events Schedule
Archive

Training

Upcoming Courses & Workshops

Pharsight� Events Archive

Pharsight is pleased to provide archived presentations and case studies for viewing at your convenience from its modeling and simulation seminar series and from online webcasts.

Seminars and Workshops

Combining PK/PD Data Analysis with an On-Demand Data Repository
April 22, 2010 (Copenhagen, Denmark)

Pharsight PK/PD Analysis and Reporting in the Drug Development Lifecycle
September 9, 2008 (Boston, Massachusetts)

Pitfalls and Challenges in Bridging from Preclinical to Phase I
September 4, 2008 (Burlingame, California)

European Modeling and Simulation Seminar
May 30, 2008 (Paris, France)

How 20 Major Companies and FDA Have Leveraged WinNonlin� to
Build Compliant and Productive PK Workflows
March 13, 2007 (Burlingame, California)

How 20 Major Companies and FDA Have Leveraged WinNonlin� to
Build Compliant and Productive PK Workflows
March 7, 2007 (East Brunswick, New Jersey)

Challenges in the Adoption of Modeling and Simulation to Support Model-Based Drug Development: An Interactive Workshop
September 6, 2006 (Brussels, Belgium)

Online Events (Webcasts)

The following online events are available for review or audio-video replay:

Overview of Validation and the Phoenix WinNonlin Validation Suite

Dates: July 7 & 22, 2010
Time: 10:00am - 11:00pm EDT
Speaker: Debra Fontana, Quality Assurance Manager

This webinar provides an overview of the reasons for computer system validation, how it is performed, and how Pharsight validation products assist in the completion of validation activities. The session also includes a tour of Pharsight’s recently released Phoenix WinNonlin Validation Suite product, which significantly reduces the time, effort, and cost of on-site validation.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

New Tools for High Throughput Preclinical/Tox Analysis and Reporting

Date: May 12, 2010
Time: 11:00am - 12:00pm EST
Speaker: Anne-Louise Menard, M.Sc., Associate Scientist

This webinar demonstrates the use of new workflow tools in Phoenix, Pharsight's desktop analysis and modeling platform, for efficient preclinical PK data management, analysis, modeling, and preparation of tables, figures, and listings within a single integrated environment.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Getting Up and Running with Pharsight's Phoenix� Applications

Date: March 2, 2010
Time: 11:00am - 12:00pm EST
Speakers: Ana Henry, M.S., Director of Product Management; Tyler Tibbits, MBA, Product Marketing Manager

This webinar provides important information on how to get up and running with Pharsight’s groundbreaking Phoenix platform applications: Phoenix� WinNonlin�, Phoenix� Connect?, and Phoenix� NLME?. Covered topics include installation requirements, supported platforms, licensing, migration pathways, and processes for deploying Phoenix applications.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Comparing Models within Phoenix NLME

Date: December 1, 2009
Time: 11:00am - 12:00pm EST
Speaker: Ana Henry, M.S., Director of Product Management Desktop Products

This webinar introduces the ‘Phoenix Model Comparer’ object within Phoenix NLME, which provides the capability to compare results of population models, combine comparison results within a spreadsheet, compare plots side by side, and to perform log-likelihood ratio tests for nested models.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Migration Pathways to Phoenix NLME? for WinNonlin Classic Users

Date: November 17, 2009
Time: 11:00am - 12:00pm EST
Speaker: Ana Henry, M.S., Director of Product Management Desktop Products

This webinar provides an introduction on how WinNonlin 5x users can begin transitioning to Phoenix NLME. It covers an overview of the differences between using WinNonlin 5 classical PK models and how to write them as Phoenix WinNonlin models when doing individual modeling. A live demonstration illustrates the transition from an individual Phoenix model to a population-based model. The webinar also demon-strates how results from NCA or other WinNonlin classical models can be used as initial estimates for population modeling. Steps for translating ASCII model to PML code are also reviewed.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Introducing Phoenix NLME?

Date: October 22, 2009
Time: 11:00am - 12:00pm EST
Speaker: Daniel Weiner, Ph.D., Sr. Vice President & CTO

This webinar provides an overview and demonstration of Phoenix NLME 1.0, the next generation population modeling application. The demonstration will focus on the major features of Phoenix NLME 1.0, including: its outstanding pre- and post-processing data management tools; a look at the range of optimization engines available; how to build models using NLME’s built-in library, graphical modeling tool, or by coding with text; how to compare various models; as well as its integration with Phoenix? WinNonlin� and Phoenix Connect?.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Optimizing Oncology Development with Modeling and Simulation

Date: October 14, 2009
Time: 11:00am - 12:00pm EST
Speaker: Rene Bruno, Ph.D., Managing Dir., Strategic Consulting Services, Europe

This webinar introduces a causal drug-disease modeling framework to predict clinical endpoints and support oncology drug development. Several case studies will illustrate how to enhance learning from early clinical data by using all available information and therefore, reducing uncertainty in understanding of drug response that contributes to better decision-making and design of later phase trials. Case examples and discussion topics include: Use of model-based approaches to achieve a more informative analysis of clinical trial data; designing Phase II studies to assess dose response and schedule dependence; dose response simulations to support dose selection and label; use of the FDA NSCLC modeling framework to simulate expected survival and Phase III trials.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

PKS Online? - Access to PKS From Anywhere at Anytime

Date: August 11, 2009
Time: 11:00am - 12:00pm EST
Speaker: Peter Schaefer, Ph.D., Director of Product Management

This webinar introduces PKS Online, an Internet-accessible implementation of PKS that provides productivity benefits for PK/PD data management, analysis and reporting tasks, in addition to compliance with existing FDA Electronic Records/Electronic Signatures regulations. For PKS Online, Pharsight has partnered with a leader in the Software-as-a-Service arena to bring the benefits of PKS to every desktop without the need to invest time and money into deploying PKS in a company’s IT environment. Using a standard desktop computer and a standard network connection, users can access PKS Online through a secured channel from virtually anywhere and at anytime.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Combatting Clinical Attrition With Quantitative Translational Medicine

Date: July 23, 2009
Time: 11:00am - 12:00pm EST
Speaker: Jonathan K. Wagg, M.D., Ph.D., Senior Scientist

This webinar defines and discusses the emerging discipline of Translational Medicine from the perspective of regulatory authorities. The problem of late stage attrition and the potential role of Translational Medicine to improve success rates for clinical development programs is also covered. This sets the context for a more detailed discussion of the field and of the related, emerging field of quantitative Translational Medicine as an upstream extension of the current model-based drug development paradigm typically applied to the clinical phases of drug development. Opportunities facing this emerging discipline are also outlined.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Introducing Phoenix Connect? 1.0

Date: July 1, 2009
Time: 11:00am - 12:00pm EST
Speaker: Jason Chittenden, M.S., Director of Product Quality

This webinar provides an overview and demonstration of how Phoenix Connect enables interoperability between SAS, S-PLUS, NONMEM, and CDISC data sources while providing scientists the rich features of the Phoenix platform. The demonstration features several specific examples of how Phoenix Connect can be used to enhance the efficiency of data management, analysis, and modeling tasks.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

A Comparison of Phoenix? WinNonlin� 6.0 and WinNonlin� 5.2.1

Date: June 16, 2009
Time: 11:00am - 12:00pm EST
Speaker: Ana Henry, M.S., Director of Product Management

This webinar provides a detailed comparison of Phoenix WinNonlin 6.0 and WinNonlin 5.2.1 within the context of a standard noncompartmental pharmacokinetic analysis.� The comparison covers creating graphs, running an NCA analysis, and generating tables.� The presentation also demonstrates how to refresh out of synch workflows and how to reuse previous workflows using new datasets via the new Phoenix WinNonlin 6.0 template feature.�

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Introducing Phoenix? WinNonlin� 6.0

Date: June 11, 2009
Time: 11:00am - 12:00pm EST
Speaker: Daniel Weiner, Ph.D., Sr. Vice President & CTO

This webinar provides an overview and demonstration of Phoenix WinNonlin 6.0, the next generation of the industry standard software tool for PK/PD modeling and noncompartmental analysis. The demonstration covers the major features of Phoenix WinNonlin 6.0, including: new workflow functionality for easy visual creation and reuse of PK/PD analyses, data visualization tools and high quality graphics, enhanced modeling capabilities, and a new underlying architecture to facilitate integration with third-party modeling and analysis tools.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Combining Technology and PK/PD Expertise to Optimize Drug Development: A New Era for Collaborative Environments in Translational Medicine

Date: April 22, 2009
Time: 1:00pm - 2:00pm EST
Speakers: JF Marier, Ph.D., FCP,�Vice President and Lead Scientist, Reporting and Analysis Services; Mark LJ Reimer, Ph.D.,�Senior Director, Reporting and Analysis Services

This webinar covers integrated approaches for data management, PK/PD analysis, reporting technology and automation to optimize drug development. Collaborative platforms for efficient translational medicine activities are also presented. Illustrative case studies provide an overview of approaches and tools used by Pharsight in the drug development process for: (i) preclinical analysis and modeling to support first-in-human dose selection (ii) Phase I/II study analysis to support efficient protocol design (iii) population PK/PD modeling to support progam decision-making (iv) regulatory submissions, CDISC and data transfer.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Using the Clinical Utility Index (CUI) to Inform Dose Selection Decisions: Integrated Modeling and Simulation Approach in Alzheimer's Disease

Date: February 4, 2009
Time: 11:00am - 12:00pm EST
Speaker: Lee Hodge, MBA, Senior Scientist, Strategic Consulting Services

This webinar covers the strategic use and value of developing utility metrics that explicitly quantify tradeoffs for clinical and commercial success to support dose selection in clinical drug development. The webinar illustrates how Pharsight's quantitative framework combines development of a Clinical Utility Index (CUI) with drug-disease models to predict drug performance versus competing treatments. The presentation includes an applied case example of dose selection using CUI and discusses extensions of the model-based CUI framework to support other drug development decisions.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Pharsight's Preclinical Automation Framework

Date: January 28, 2009
Time: 11:00am - 12:00pm EST
Speaker: Jeff Fischer, PharmD, Manager, PK Automation & Deployment Services

This webinar provides an overview and demonstration of Pharsight's Preclinical Automation Framework (PAF), a software application that provides preclinical development organizations with a systematic approach to automate preclinical PK analyses, creation of high-quality graphs and tables, and export to Microsoft Word and Powerpoint for use in regulatory and internal reports and presentations. PAF provides analysis outputs for preclinical reports in an expedited manner while increasing quality with minimal study data setup required.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Pharsight's Critical Path Approach for Development of Generic Products

Date: November 12, 2008
Time: 10:00am - 11:00am EST
Speakers: Jean-Francois Marier, PhD, FCP, Vice President & Lead Scientist, Reporting and Analysis Services; Jean-S�bastien Brunet, MSc, Senior Associate, Statistics and Data Management, Reporting and Analysis Services.

This webinar presents state-of-the-art pharmacokinetic and statistical analyses that can be used to assess bioequivalence of locally acting and highly variable drugs. The webinar will also present multiple examples showing how Pharsight's approach can save time and money in the development of a generic product with the use of�IVIVC, biowaivers, bioassay validation, short-paneled or under-recruited studies, interim analysis, sequential bioequivalence studies, and sample pooling for preliminary assessment of bioequivalence.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Saving Time and Money With Better Preclinical Planning

Date: August 6, 2008
Time: 10:00am - 11:00am EDT
Speaker: Mark LJ Reimer, Ph.D., Senior Director, Operations and Preclinical Development, Reporting and Analysis Services

Many drug development failures can be attributed to a lack of proper planning and execution at the early preclinical assessment stages. Asking the right questions at the right time is the key to strategic drug development planning. Drug development can be viewed as a process that proceeds through several key go/no-go 'decision gates'. This webinar will review key decisions in early stage development that drive the goals of generating viable clinical candidates, shortening the development process, and reducing attrition rates.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Population PK/PD Modeling: The Pharsight Approach

Date: June 26, 2008
Time: 10:00am - 11:00am EDT
Speaker: Dan Weiner, Ph.D., Senior Vice President and Chief Technology Officer

Provides an overview of the approaches and tools used by the Pharsight Reporting and Analysis Services (RAS) Group for regulatory-quality population PK/PD modeling, including: analysis planning, dataset construction, base model building (structural and statistical), addition of covariates, checking of assumptions, model evaluation, parameter estimation, predictions, and sensitivity analysis.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Portable Concepts for HCV & HIV Drug-Disease Modeling and Prediction

Date: February 28, 2008
Time: 10:00am - 11:00am PDT
Speaker: Bill Poland, Ph.D., VP and Lead Scientist, Strategic Consulting Services

Covers the use and strategic value of integrated modeling and simulation of pharmacokinetics, pharmacodynamics, adherence, and trial outcomes for HCV and HIV drugs. Despite important differences such as the potential to cure HCV and faster HCV dynamics, HCV trial outcomes can be predicted and improved by model-informed design, as for HIV.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Modeling and Simulation of QTc Prolongation

Date: January 23, 2008
Time: 10:00am - 11:00am PDT
Speaker: TJ Carrothers, Sc.D., Senior Scientist, Strategic Consulting Services

Prolongation of the QT interval has emerged as an important biomarker in cardiac safety assessment in drug development. Concentration-effect modeling, as promoted by the US FDA, is an important component in assessing QT-related risk. This webinar provides an overview of modeling and simulation applications, and their associated benefits for improving drug development, both in the context of the thorough-QT study as well as in the pooled analysis of Phase I/II studies.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Dose Optimization Case Studies

Date: December 11, 2007
Time: 11:00am - 12:00pm EST
Speaker: Dan Weiner, Ph.D., Chief Technology Officer

Covers a review of five case studies, from a variety of therapeutic domains, where PK/PD modeling and simulation was used to optimize dose selection.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Using DMX� to Communicate Model-Based Product Profiles

Date: October 23, 2007
Time: 1:00pm - 2:00pm EDT (6pm GMT, 10am PDT)
Speaker: Klaas Prins, Ph.D., Senior Scientist, Strategic Consulting Services

Overview of how DMX software can make complex information about modeled drug effects accessible to clinical development teams to explore strategic development questions. Includes applied case study and product demonstration.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Using Pharsight Trial Simulator? for Improved Trial Design

Date: August 23, 2007
Time: 1:00pm - 2:00pm EDT (US)
Speaker: Daniel Weiner, Ph.D., Senior Vice President & Chief Technology Officer

Overview of the rationale for Computer Assisted Trial Design (CATD), CATD process and methods, and demonstration of Pharsight Trial Simulator? software.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Improving PK/PD Workflow Integration with PKS?

Date: August 9, 2007
Time: 11:00am - 12:00pm GMT
Speaker: Simon Davis, Senior Scientific Consultant, Training and Pre-Sales

Overview and demonstration of how Pharsight Knowledgebase Server? (PKS?) provides the technical infrastructure to effectively and securely manage PK/PD data and associated analyses across development programs or indications.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Using WinNonlin AutoPilot for PK Analysis and Reporting

Date: July 31, 2007
Time: 1:00pm - 2:00pm EDT (US)
Speaker: Joannellyn Chiu, PhD, Scientific Consultant, Training, Pre-Sales & Support

Overview and demonstration of how WinNonlin AutoPilot can automate scriptable noncompartmental analysis and reporting.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

IVIVC Applications and Case Studies

Date: July 25, 2007
Time: 1:00pm - 2:00pm EDT (US)
Speakers: JF Marier, MSc, PhD, Vice President, Reporting and Analysis Services; Jason Chittenden, MS, Product Manager, WinNonlin� & IVIVC Toolkit? for WinNonlin

Overview of In Vivo-In Vitro Correlation (IVIVC) approaches, strategies and regulation; two applied IVIVC case studies; introduction to Pharsight software for conducting IVIVC analyses.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Using Biomarker and Literature Data in Type II Diabetes

Date: May 30, 2007
Time: 1:00pm - 2:00pm EDT (US)
Speakers: Jill Fredrickson, Ph.D., Senior Scientist, Strategic Consulting Services; Todd Barbee, R.Ph., Manager of Clinical Database Services

Covers the strategic use and value of assessing, extracting and modeling public-domain scientific literature to support clinical drug development decision-making. An applied case example illustrates how development of literature-based disease models can be used to generate insights into the treatment of Type II diabetes. Beyond the case example, issues and considerations for combining public-source literature data with proprietary NCE data are discussed.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Quantitative Approaches for Predicting First-in-Man Dosing Regimens

Date: May 21, 2007
Time: 1:00pm - 2:00pm EDT (US)
Speaker: Jonathan K. Wagg, M.D., Ph.D., Senior Scientist, Strategic Consulting Services

Covers the strategic use and value of modeling and simulation to support translational drug development decision-making. Case examples are used to illustrate key approaches for the scaling of pharmacokinetic and pharmacodynamic data from preclinical studies and public domain data to human subjects to support first-in-man (FIM) dosing regimen design and optimization. Relevant regulatory issues and considerations are also discussed, including regulatory perspectives and current activities under FDA’s Critical Path Initiative.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Perspectives on Modeling & Simulation and the Critical Path Initiative

Date: April 17, 2007
Time: 9:00am ? 10:00am Japan local time
Speakers: Daniel Weiner, Ph.D., Senior Vice President & Chief Technology Officer; Kunihiro Sasahara, Ph.D., Japanese Business Development, Pharsight Corporation

The webinar discusses FDA's view on the role of modeling and simulation in drug development and approval and describes how biopharmaceutical companies and FDA are building the technology and organizational infrastructure to support model-based drug development. The program covers:

The regulatory and commercial imperatives for modeling
FDA’s Critical Path Initiative
The evolving needs for technical infrastructure to support model-based drug development

The webinar concludes with a question and answer session on the practical challenges and considerations for implementing model-based drug development in today’s leading organizations.

Replay Event Now (sign-in required)

View Presentation Slides in Japanese (sign-in required)

IVIVC Toolkit for WinNonlin: Product Introduction & Demonstration

Date: October 25, 2006
Time: 11:00am EDT (US)
Speaker: Jason Chittenden, Product Marketing Manager

This webinar provides an overview and demonstration of the IVIVC Toolkit for WinNonlin, an add-in toolkit for WinNonlin that extends its capabilities beyond pharmacokinetic, pharmacodynamic, and non-compartmental analysis to the development and application of in vivo-in vitro correlations (IVIVC). The product overview and demonstration covers the Toolkit's enhanced deconvolution methods, numerical convolution, new plotting capability, and describes benefits of the "IVIVC Wizard" for pharmacokineticists and formulators.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Computer System Validation and Pharsight Validation Products

Date: August 29, 2006
Time: 10:00am EDT (US)
Speaker: Debra Fontana, Quality Assurance Manager, Software Products Group

Covers software and computer systems validation terminology, regulations and guidelines for validating computer systems in FDA-regulated environments. The presentation covers:

Current status of validation requirements in FDA-regulated industries
Responsibilities of software vendors vs. software users with regard to validation
Phases of a validation life cycle model
Current status of 21 CFR Part 11
How Pharsight validation products assist in the completion of the validation life cycle

The session includes a demonstration of Pharsight’s WinNonlin Validation Suite product, which streamlines the on-site validation of WinNonlin. The Validation Suite provides a selection of automated tests, each of which runs a specific WinNonlin analysis or function and tests the results against standardized, known output, along with valuable document templates.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Modeling & Simulation to Foster Collaborative Decision-Making

Date: June 14, 2006
Time: 11:00am EDT US
Speaker: Kevin Dykstra, Ph.D., Senior Scientist, Strategic Consulting Services

Covers how quantitative modeling and simulation (M&S) can foster collaborative decision-making across functional development team members and with senior R&D management. The term M&S is shorthand for a set of integrated methods and tools that help navigate the inherent complexity and uncertainty in clinical drug development. An applied case study illustrates:

How PK/PD modeling can be used to create integrated assessments of a compound's clinical utility and commercial potential
How tools to visualize and explore model-based product profiles can make complex information accessible to clinicians and other non-modelers
How the above methods and tools helped identify specific, actionable recommendations for the drug program team

Beyond the case example, issues and considerations for extending the analysis to explicitly address financial recommendations are also discussed.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Modeling and Simulation to Support Strategic Management of CNS Product Lifecycle

Date: May 25, 2006
Time: 2:00pm EDT US (18:00 GMT)
Speaker: Bob Korsan, M.S.,M.A., Senior Scientist, Strategic Consulting Services

Covers the multi-year collaboration between Cephalon and Pharsight to use decision-focused drug-disease modeling, simulation and trial design to assist Cephalon in the development of a sequence of compounds and formulations in its flagship CNS product franchise. Provigil? and its associated products are used in the treatment of narcolepsy (NARC), obstructive sleep apnea (OSA), shift work sleep disorder (SWSD) and attention deficit hyperactivity disorder (ADHD). Case examples of modeling and simulation approaches from the collaborative engagement demonstrate:

How trial arms were eliminated
How model-based dose selection dramatically shortened time-to-market
How dose-regimen was tailored to improve efficacy in the face of complex pharmacodynamics
How Cephalon used model recommendations based on early phase trial data to proceed to confirmatory trials, manage risk and uncertainty, and provide a steady stream of evidence for the FDA to enlarge the pool of patients who gain medically significant benefit .

Beyond the case examples, issues and considerations for applying decision-focused modeling and simulation to clinical development, indication sequencing and formulation selection are also discussed.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Modeling and Decision Analysis to Support Formulation Selection and Trial Sequencing

Date: April 11, 2006
Time: 10:30am ? 11:30am PDT (US)
Speaker: Bob Korsan, M.S.,M.A., Senior Scientist & Director of Decision Services

Covers the use and strategic value of integrated modeling and simulation/decision analysis (DA) to assist with important development decisions by maximizing learning and making quantitative assessments of compound/NCE value. An applied case example illustrates:

How modeling/DA helped recommend the choice and order of formulation development
How modeling/DA recommended skipping a trial to shorten development
How a model of market value can be applied to difficult development decisions

Beyond the case example, issues and considerations for applying integrated modeling/DA techniques to decisions ranging from compound progression to portfolio selection are also discussed.

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Modeling and Simulation to Support HIV Drug Development Decisions

Date: February 28, 2006
Time: 10:30am ? 11:30am PST (US)
Speaker: Bill Poland, Ph.D, Senior Scientist, Strategic Consulting Services

Covers the use and strategic value of integrated adherence-PK-PD-trial modeling and simulation for antiretrovirals approaching Phase 2 or 3 development. Case examples illustrate:

How modeling helped Pfizer plan Phase 2 and 3 for maraviroc
How benchmarking against a better understood drug can help in dose selection
How a model of market value can be applied to difficult development decisions

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Model-Based Meta-Analysis for Integration of Data from Multiple Sources

Date: February 15, 2006
Time: 11:30am ? 12:30pm EST (US)
Speaker: Bill Gillespie, Ph.D, Lead Scientist and VP, Strategic Consulting Services

Covers the use and strategic value of model-based meta-analysis to support clinical drug development decision-making, including:

Rationale for model-based meta-analysis
Overview of the data collection and modeling process
Illustrative case studies
Issues and considerations for execution and interpretation

Replay Event Now (sign-in required)

View Presentation (sign-in required)

Pharsight� Events Archive

Seminars and Workshops

Online Events (Webcasts)

Seminars and Workshops

Online Events (Webcasts)

Reporting and Analysis Services (RAS)

Strategic Consulting Services (SCS)

Software Products